Vimta Labs Ltd
VIMTALABSVimta Labs Ltd
VIMTALABS
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 33.92 | 5.31 | 0.26% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.09 | 6.40 | 0.53% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Vimta Labs Limited is engaged in providing testing and contract research services in the fields of clinical and pre-clinical studies, clinical reference, analytical testing, advanced molecular biology and environmental studies.
Investor Presentation
View olderPeers
Compare with peersDivi's Laboratories Ltd
Syngene International Ltd
Aarti Pharmalabs Ltd
Dishman Carbogen Amcis Ltd
Brooks Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 183.73 | 211.51 | 279.73 | 321.63 | 322.27 | 323.75 | ||||||
Raw Materials | 32.41 | 35.25 | 54.81 | 44.13 | 48.69 | 222.29 | ||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Employee Cost | 57.63 | 57.80 | 71.42 | 86.32 | 95.30 | |||||||
| Selling & Administrative Expenses | 26.50 | 21.73 | 28.56 | 43.23 | 38.83 | |||||||
| Operating & Other expenses | 34.22 | 42.94 | 44.43 | 49.60 | 48.65 | |||||||
EBITDA | 32.97 | 53.79 | 80.51 | 98.35 | 90.80 | 101.46 | ||||||
| Depreciation/Amortization | 20.93 | 23.08 | 23.33 | 30.71 | 34.20 | 33.05 | ||||||
| PBIT | 12.04 | 30.71 | 57.18 | 67.64 | 56.60 | 68.41 | ||||||
| Interest & Other Items | 3.77 | 2.17 | 1.50 | 2.65 | 2.12 | 1.95 | ||||||
| PBT | 8.27 | 28.54 | 55.68 | 64.99 | 54.48 | 66.46 | ||||||
| Taxes & Other Items | 1.42 | 7.14 | 14.36 | 16.83 | 13.47 | 16.45 | ||||||
| Net Income | 6.85 | 21.40 | 41.32 | 48.16 | 41.01 | 50.01 | ||||||
| EPS | 3.10 | 9.68 | 18.69 | 21.77 | 18.51 | 22.56 | ||||||
| DPS | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | ||||||
| Payout ratio | 0.00 | 0.21 | 0.11 | 0.09 | 0.11 | 0.09 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vimta Labs Ltd | 41.37 | 5.31 | 0.26% |
| Divi's Laboratories Ltd | 99.52 | 11.73 | 0.50% |
| Syngene International Ltd | 68.38 | 8.19 | 0.14% |
| Aarti Pharmalabs Ltd | 27.30 | 3.37 | 0.46% |
Price Comparison
Compare VIMTALABS with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 2.89%
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 1.85%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.49%
Top 2 Mutual Funds holding Vimta Labs Ltd
| Funds (Top 2) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0003% | Percentage of the fund’s portfolio invested in the stock 0.03% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 97/102 (-2) |
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.00% | Change in the portfolio weight of the stock over the last 3 months -0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/94 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 11, 2024
Dividend/Share
₹2.00
Ex DateEx Date
Jul 11, 2024
Cash Dividend
Ex DateEx DateJun 21, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Jun 21, 2023
Cash Dividend
Ex DateEx DateJun 16, 2022
Dividend/Share
₹2.00
Ex DateEx Date
Jun 16, 2022
Cash Dividend
Ex DateEx DateJun 25, 2021
Dividend/Share
₹2.00
Ex DateEx Date
Jun 25, 2021
Cash Dividend
Ex DateEx DateJul 18, 2019
Dividend/Share
₹2.00
Ex DateEx Date
Jul 18, 2019
Net profit of Vimta Labs rose 140.92% to Rs 15.25 crore in the quarter ended September 2024 as against Rs 6.33 crore during the previous quarter ended September 2023. Sales rose 29.30% to Rs 84.74 crore in the quarter ended September 2024 as against Rs 65.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales84.7465.54 29 OPM %35.3026.56 - PBDT30.1818.84 60 PBT21.8910.19 115 NP15.256.33 141 Powered by Capital Market - Live
Vimta Labs will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
Vimta Labs has completed the sale and transfer of its diagnostic and pathological services business as a going concern to Thyrocare Technologies on 11 October 2024. Powered by Capital Market - Live
Vimta Labs consolidated net profit rises 0.66% in the June 2024 quarter
Vimta Labs Consolidated March 2023 Net Sales at Rs 81.82 crore, up 10.44% Y-o-Y
Stocks to watch on May 3, 2023
Heranba Industries Ltd leads losers in ‘B’ group
Vimta Labs Consolidated December 2022 Net Sales at Rs 77.38 crore, up 14.92% Y-o-Y
Vimta Labs consolidated net profit rises 35.63% in the September 2022 quarter
VIMTA Labs forays into electrical, electronics testing
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant